Drug name - Xalkori

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785632 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Mar, 2025

(2 years from now)

US7230098 PF PRISM CV Aminoheteroaryl compounds as protein kinase inhibitors
Aug, 2025

(2 years from now)

US7858643 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Oct, 2029

(7 years from now)

US8217057 PF PRISM CV Polymorphs of a c-MET/HGFR inhibitor
Nov, 2029

(7 years from now)

CN103265477A PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

CN103265477B PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

CN101023064B PF PRISM CV As Protein Kinase Inhibitors Of Enantiomer Pure Amino Heteroaryl Compound
Aug, 2025

(2 years from now)

CN101023064A PF PRISM CV The Enantiomer Pure Amino Heteroaryl Compound As Protein Kinase Inhibitor
Aug, 2025

(2 years from now)

CN101326175B PF PRISM CV Polymorphs Of A C-Met/Hgfr Inhibitor
Nov, 2026

(4 years from now)

CN101326175A PF PRISM CV Polymorphs Of A C-Met/Hgfr Inhibitor
Nov, 2026

(4 years from now)

IN200503734P1 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

IN249316B PF PRISM CV An Amino-Pyridine Compound Of Formula I
Feb, 2024

(1 year, 4 months from now)

IN200700144P1 PF PRISM CV Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Aug, 2025

(2 years from now)

IN250050B PF PRISM CV An Enantiomerically Pure Aminopyridine Compound Of Formula (I)
Aug, 2025

(2 years from now)

EP1603570A2 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP2476667A2 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP1603570A4 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP2476667B1 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP2476667A3 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP1603570B9 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP1603570B1 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP1963302B1 PF PRISM CV Polymorphs Of A C-Met/Hgfr Inhibitor
Nov, 2026

(4 years from now)

EP1963302A2 PF PRISM CV Polymorphs Of A C-Met/Hgfr Inhibitor
Nov, 2026

(4 years from now)

EP1786785A2 PF PRISM CV Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Oct, 2027

(5 years from now)

EP1786785B1 PF PRISM CV Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Oct, 2027

(5 years from now)

EP1786785B9 PF PRISM CV Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Oct, 2027

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7825137 PF PRISM CV Method of treating abnormal cell growth May, 2027

(4 years from now)

Drugs and Companies using CRIZOTINIB ingredient

Treatment: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive; treatment of patients with metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
200MG CAPSULE;ORAL Prescription
250MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.